Artificial Intelligence (AI) aimed at detecting skin cancer is not yet ready for use in primary care settings, due to a lack of evidence in settings where the prevalence of skin cancer is low, according to CanTest researchers.
The NeutroCheck is a point-of-care medical device which can be used by patients outside of hospital to monitor their risk of neutropenic sepsis, a potentially life-threatening complication of chemotherapy.
Millions of pounds in funding has been announced for a trial that could pave the way for a ‘sponge on a string’ test to be established as a routine screening programme to detect Barrett’s oesophagus – a condition that can lead to oesophageal cancer.